Demographic and clinical characteristics of 16 not-transplanted Huntington's disease patients
| ID | Sex | Onset age in years (calendar year) | Years of education | CAG repeats | Affected parent | Symptom at onset | DB | Drugs (mg/day) |
|---|---|---|---|---|---|---|---|---|
| 11 | M | 47 (2003) | 14 | 44 | Mother | Cognitive | 399 | PMZ (2); TBZ (25); STR (100) |
| 12 | M | 38 (2002) | 8 | 47 | Mother | Psychiatric | 437 | VPA (1500); TBZ (125); APM (0.5) |
| 13 | F | 45 (2002) | 18 | 50 | Father | Motor | 652 | VPA (150); TBZ (25) |
| 14+ | M | 30 (1992) | 8 | 49 | Father | Motor | 405 | PMZ (4); APM (0.5) |
| 15 | M | 30 (2000) | 5 | 47 | Unknown | Motor | 345 | TBZ (25) |
| 16 | M | 40 (2000) | 8 | 45 | Mother | Motor | 380 | VPA (600); PMZ (4); APM (0.5); STR (50) |
| 17+ | F | 39 (1996) | 5 | 50 | Father | Cognitive | 565 | PMZ (2) |
| 18 | F | 37 (1997) | 5 | 47 | Unknown | Psychiatric | 425 | None |
| 19 | M | 55 (2003) | 5 | 47 | Mother | Psychiatric | 632 | PMZ (2); TBZ (25) |
| 20 | F | 50 (2002) | 5 | 43 | Mother | Psychiatric | 375 | APM (0.25); STR (50) |
| 21 | F | 44 (1996) | 16 | 47 | Unknown | Psychiatric | 506 | PMZ (0.5); TBZ (37.5); STR (50) |
| 22 | F | 56 (2000) | 8 | 38 | Mother | Motor | 140 | PMZ (6); TPR (200); AMD (200) |
| 23 | M | 59 (2004) | 8 | 42 | Father | Motor | 383 | VPA (1100); APM (0.5); STR (75) |
| 24 | F | 57 (2004) | 5 | 40 | Unknown | Motor | 256 | STR (50) |
| 25 | M | 40 (2004) | 13 | 43 | Father | Motor | 300 | AMD (200) |
| 26+ | F | 36 (1994) | 8 | 44 | Mother | Motor | 306 | VPA (300); STR (25) |
+, patient who died; AMD, amantadine; APM, alprazolam; CAG, cytosine-adenine-guanine; DB, disease burden measured as (CAG number–35.5)×age-at-onset23; F, female; ID, patient identifier; M, male; PMZ: pimozide; STR, sertraline; TBZ, tetrabenazine; TPR, tiapride; VPA, sodium valproate.